Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer

计划入组 29 人 · 首次发布于 2022 年 8 月 9 日

KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma

计划入组 80 人 · 首次发布于 2023 年 8 月 14 日

TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer

计划入组 80 人 · 首次发布于 2024 年 9 月 19 日

Colorectal cancer vaccine (Oryx)

Colorectal Cancer(Envisagenics)

Colorectal Cancer(Dewpoint)

Austrian Breast & Colorectal Cancer Study Group

Austria

BORDEAUX COLORECTAL INSTITUTE ACADEMY

France

CENTER WEST CANCER

United States

Trastuzumab/Pertuzumab Shows Promise for HER2-Positive Metastatic Colorectal Cancer

Global Colon Cancer Association to Host Webinar on HER2-Positive Colorectal Cancer and Biomarker Testing for Patient Advocates

Tucatinib-Trastuzumab Combination Shows Promise in HER2-Positive, RAS Wild-Type Colorectal Cancer